Cargando…
Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers
BACKGROUND: While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5(+) mesenchymal stem cells (MSCs) might provide a new adjunctive...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444095/ https://www.ncbi.nlm.nih.gov/pubmed/36064604 http://dx.doi.org/10.1186/s13287-022-03156-9 |
_version_ | 1784783139618422784 |
---|---|
author | Kerstan, Andreas Dieter, Kathrin Niebergall-Roth, Elke Klingele, Sabrina Jünger, Michael Hasslacher, Christoph Daeschlein, Georg Stemler, Lutz Meyer-Pannwitt, Ulrich Schubert, Kristin Klausmann, Gerhard Raab, Titus Goebeler, Matthias Kraft, Korinna Esterlechner, Jasmina Schröder, Hannes M. Sadeghi, Samar Ballikaya, Seda Gasser, Martin Waaga-Gasser, Ana M. Murphy, George F. Orgill, Dennis P. Frank, Natasha Y. Ganss, Christoph Scharffetter-Kochanek, Karin Frank, Markus H. Kluth, Mark A. |
author_facet | Kerstan, Andreas Dieter, Kathrin Niebergall-Roth, Elke Klingele, Sabrina Jünger, Michael Hasslacher, Christoph Daeschlein, Georg Stemler, Lutz Meyer-Pannwitt, Ulrich Schubert, Kristin Klausmann, Gerhard Raab, Titus Goebeler, Matthias Kraft, Korinna Esterlechner, Jasmina Schröder, Hannes M. Sadeghi, Samar Ballikaya, Seda Gasser, Martin Waaga-Gasser, Ana M. Murphy, George F. Orgill, Dennis P. Frank, Natasha Y. Ganss, Christoph Scharffetter-Kochanek, Karin Frank, Markus H. Kluth, Mark A. |
author_sort | Kerstan, Andreas |
collection | PubMed |
description | BACKGROUND: While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5(+) mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing and engraftment potential, their ability to adaptively respond to inflammatory signals, and their wound healing-promoting efficacy in mouse wound models and human chronic venous ulcers. METHODS: The angiogenic potential of ABCB5(+) MSCs was characterized with respect to angiogenic factor expression at the mRNA and protein level, in vitro endothelial trans-differentiation and tube formation potential, and perfusion-restoring capacity in a mouse hindlimb ischemia model. Finally, the efficacy and safety of ABCB5(+) MSCs for topical adjunctive treatment of chronic, standard therapy-refractory, neuropathic plantar DFUs were assessed in an open-label single-arm clinical trial. RESULTS: Hypoxic incubation of ABCB5(+) MSCs led to posttranslational stabilization of the hypoxia-inducible transcription factor 1α (HIF-1α) and upregulation of HIF-1α mRNA levels. HIF-1α pathway activation was accompanied by upregulation of vascular endothelial growth factor (VEGF) transcription and increase in VEGF protein secretion. Upon culture in growth factor-supplemented medium, ABCB5(+) MSCs expressed the endothelial-lineage marker CD31, and after seeding on gel matrix, ABCB5(+) MSCs demonstrated formation of capillary-like structures comparable with human umbilical vein endothelial cells. Intramuscularly injected ABCB5(+) MSCs to mice with surgically induced hindlimb ischemia accelerated perfusion recovery as measured by laser Doppler blood perfusion imaging and enhanced capillary proliferation and vascularization in the ischemic muscles. Adjunctive topical application of ABCB5(+) MSCs onto therapy-refractory DFUs elicited median wound surface area reductions from baseline of 59% (full analysis set, n = 23), 64% (per-protocol set, n = 20) and 67% (subgroup of responders, n = 17) at week 12, while no treatment-related adverse events were observed. CONCLUSIONS: The present observations identify GMP-manufactured ABCB5(+) dermal MSCs as a potential, safe candidate for adjunctive therapy of otherwise incurable DFUs and justify the conduct of a larger, randomized controlled trial to validate the clinical efficacy. Trial registration: ClinicalTrials.gov, NCT03267784, Registered 30 August 2017, https://clinicaltrials.gov/ct2/show/NCT03267784 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03156-9. |
format | Online Article Text |
id | pubmed-9444095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94440952022-09-06 Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers Kerstan, Andreas Dieter, Kathrin Niebergall-Roth, Elke Klingele, Sabrina Jünger, Michael Hasslacher, Christoph Daeschlein, Georg Stemler, Lutz Meyer-Pannwitt, Ulrich Schubert, Kristin Klausmann, Gerhard Raab, Titus Goebeler, Matthias Kraft, Korinna Esterlechner, Jasmina Schröder, Hannes M. Sadeghi, Samar Ballikaya, Seda Gasser, Martin Waaga-Gasser, Ana M. Murphy, George F. Orgill, Dennis P. Frank, Natasha Y. Ganss, Christoph Scharffetter-Kochanek, Karin Frank, Markus H. Kluth, Mark A. Stem Cell Res Ther Research BACKGROUND: While rapid healing of diabetic foot ulcers (DFUs) is highly desirable to avoid infections, amputations and life-threatening complications, DFUs often respond poorly to standard treatment. GMP-manufactured skin-derived ABCB5(+) mesenchymal stem cells (MSCs) might provide a new adjunctive DFU treatment, based on their remarkable skin wound homing and engraftment potential, their ability to adaptively respond to inflammatory signals, and their wound healing-promoting efficacy in mouse wound models and human chronic venous ulcers. METHODS: The angiogenic potential of ABCB5(+) MSCs was characterized with respect to angiogenic factor expression at the mRNA and protein level, in vitro endothelial trans-differentiation and tube formation potential, and perfusion-restoring capacity in a mouse hindlimb ischemia model. Finally, the efficacy and safety of ABCB5(+) MSCs for topical adjunctive treatment of chronic, standard therapy-refractory, neuropathic plantar DFUs were assessed in an open-label single-arm clinical trial. RESULTS: Hypoxic incubation of ABCB5(+) MSCs led to posttranslational stabilization of the hypoxia-inducible transcription factor 1α (HIF-1α) and upregulation of HIF-1α mRNA levels. HIF-1α pathway activation was accompanied by upregulation of vascular endothelial growth factor (VEGF) transcription and increase in VEGF protein secretion. Upon culture in growth factor-supplemented medium, ABCB5(+) MSCs expressed the endothelial-lineage marker CD31, and after seeding on gel matrix, ABCB5(+) MSCs demonstrated formation of capillary-like structures comparable with human umbilical vein endothelial cells. Intramuscularly injected ABCB5(+) MSCs to mice with surgically induced hindlimb ischemia accelerated perfusion recovery as measured by laser Doppler blood perfusion imaging and enhanced capillary proliferation and vascularization in the ischemic muscles. Adjunctive topical application of ABCB5(+) MSCs onto therapy-refractory DFUs elicited median wound surface area reductions from baseline of 59% (full analysis set, n = 23), 64% (per-protocol set, n = 20) and 67% (subgroup of responders, n = 17) at week 12, while no treatment-related adverse events were observed. CONCLUSIONS: The present observations identify GMP-manufactured ABCB5(+) dermal MSCs as a potential, safe candidate for adjunctive therapy of otherwise incurable DFUs and justify the conduct of a larger, randomized controlled trial to validate the clinical efficacy. Trial registration: ClinicalTrials.gov, NCT03267784, Registered 30 August 2017, https://clinicaltrials.gov/ct2/show/NCT03267784 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-03156-9. BioMed Central 2022-09-05 /pmc/articles/PMC9444095/ /pubmed/36064604 http://dx.doi.org/10.1186/s13287-022-03156-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kerstan, Andreas Dieter, Kathrin Niebergall-Roth, Elke Klingele, Sabrina Jünger, Michael Hasslacher, Christoph Daeschlein, Georg Stemler, Lutz Meyer-Pannwitt, Ulrich Schubert, Kristin Klausmann, Gerhard Raab, Titus Goebeler, Matthias Kraft, Korinna Esterlechner, Jasmina Schröder, Hannes M. Sadeghi, Samar Ballikaya, Seda Gasser, Martin Waaga-Gasser, Ana M. Murphy, George F. Orgill, Dennis P. Frank, Natasha Y. Ganss, Christoph Scharffetter-Kochanek, Karin Frank, Markus H. Kluth, Mark A. Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title | Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title_full | Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title_fullStr | Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title_full_unstemmed | Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title_short | Translational development of ABCB5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
title_sort | translational development of abcb5(+) dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444095/ https://www.ncbi.nlm.nih.gov/pubmed/36064604 http://dx.doi.org/10.1186/s13287-022-03156-9 |
work_keys_str_mv | AT kerstanandreas translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT dieterkathrin translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT niebergallrothelke translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT klingelesabrina translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT jungermichael translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT hasslacherchristoph translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT daeschleingeorg translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT stemlerlutz translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT meyerpannwittulrich translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT schubertkristin translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT klausmanngerhard translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT raabtitus translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT goebelermatthias translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT kraftkorinna translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT esterlechnerjasmina translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT schroderhannesm translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT sadeghisamar translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT ballikayaseda translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT gassermartin translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT waagagasseranam translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT murphygeorgef translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT orgilldennisp translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT franknatashay translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT gansschristoph translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT scharffetterkochanekkarin translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT frankmarkush translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers AT kluthmarka translationaldevelopmentofabcb5dermalmesenchymalstemcellsfortherapeuticinductionofangiogenesisinnonhealingdiabeticfootulcers |